Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%
23 oct. 2023 08h30 HE
|
Apollomics Inc.
FOSTER CITY, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), today announced the presentation of vebreltinib efficacy and safety data from the KUNPENG...
Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023
16 oct. 2023 18h55 HE
|
Apollomics Inc.
FOSTER CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to...
Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update
28 sept. 2023 16h17 HE
|
Apollomics Inc.
Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation expected second half 2023 Approximately $52.6 million in cash,...
Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
06 sept. 2023 07h00 HE
|
Apollomics Inc.
FOSTER CITY, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to...
Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposium
11 avr. 2023 08h30 HE
|
Apollomics, Inc.
FOSTER CITY, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address...
Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq
30 mars 2023 08h00 HE
|
Apollomics, Inc.
FOSTER CITY, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to...
Apollomics Inc. Receives FDA Orphan Drug Designation for Vebreltinib (APL-101) for Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor Aberrations
15 nov. 2022 08h00 HE
|
Apollomics, Inc.
FOSTER CITY, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: JMAC), an innovative biopharmaceutical company committed to the discovery and development of mono- and...
Apollomics Inc., a Late-Stage Clinical Biopharmaceutical Company to be Listed on Nasdaq Through Business Combination with Maxpro Capital Acquisition Corp.
14 sept. 2022 08h30 HE
|
Apollomics, Inc.
– Transaction values Apollomics at pre-money equity value of $899 million– Apollomics is a late-stage clinical biopharmaceutical company developing innovative product candidates for large, unmet...
Apollomics Inc. Expands Leadership Team with Appointment of Jane Wang, PhD as Chief Scientific Officer
26 juil. 2022 07h10 HE
|
Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, China, July 26, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and...
Apollomics Inc. To Host Virtual Investor Events on Wednesday, January 26, 2022 and Thursday, January 27, 2022
12 janv. 2022 07h05 HE
|
Apollomics, Inc.
FOSTER CITY, Calif., SHANGHAI and HANGZHOU, China, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and...